OCT 03, 2017 3:18 PM PDT

Parkinson's Drug Activates a Cancer-Fighting Protein


Image credit: Pixabay.com

A drug commonly used to treat symptoms of Parkinson’s disease may have the capacity to stop pancreatic tumor cells from growing, reports a new study.

The current study stems from previous observations showing Parkinson’s patients seem to have a reduced incidence of cancer. Could this be because of the drugs that Parkinson’s patients take?

Common drugs prescribed to help Parkinson’s patients include carbidopa in conjunction with levodopa (L-Dopa). However, previous studies that looked into whether L-Dopa conferred anti-cancer effects did not find promising evidence.

This time, researchers from the Texas Tech University Health Sciences Center (TTUHSC) focused on carbidopa, hoping this is the drug behind the anti-cancer effects.

"Interestingly, no one has previously suspected carbidopa as a potential player in this phenomenon,” said Dr. Yangzom Bhutia, the study’s senior research author. "Carbidopa is never used by itself as a drug for any disease. But [...] we believe that the reduced incidence of most cancers in Parkinson's disease patients is due to carbidopa."

The team exposed carbidopa to human pancreatic cell lines, chosen specifically because of pancreatic cancer’s notorious reputation as one of the most ruthless killers. "Pancreatic cancer, especially the pancreatic ductal adenocarcinoma, is the most lethal of all cancers with a dismal survival rate,” said Dr. Bhutia.

With carbidopa treatment, the tumor cells were less able to form colonies, suggesting carbidopa slowed the cells’ ability to grow.

When the team tested carbidopa in a mouse model of pancreatic cancer, they observed similar promising results. Mice treated with carbidopa had smaller tumors, by volume and weight, as compared to the untreated mice.

The team also observed that carbidopa activated a protein, known as aryl hydrocarbon receptor (AhR), has been shown to have anti-cancer effects. In addition to the pancreatic cancer cell lines, activation of the AhR protein was seen in liver cancer cell lines. "Hence carbidopa could potentially be repurposed to treat pancreatic cancer and possibly other cancers as well,” the authors speculated.

"Carbidopa as an anti-cancer agent to treat pancreatic cancer would be something truly amazing. Given the fact that it is an FDA-approved drug, repurposing the same drug for cancer treatment would be tremendously cost- and time-saving,” Dr. Bhutia said. "Our laboratory is actively working to determine if there are additional targets for this drug related to its potency as an anti-cancer drug."

Of note, the most common type of pancreatic cancer is known as pancreatic ductal adenocarcinoma (PDAC). It accounts for a small percentage of all diagnosed cancer (around 3 percent), but claims an aggressive number of lives (around 7 percent of all cancer-related deaths in the US). It’s estimated that of the 53,000 Americans who will be diagnosed with pancreatic cancer this year, almost 79 percent will succumb from the disease.

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JAN 09, 2020
Drug Discovery & Development
JAN 09, 2020
Can Cancer Drugs Treat Lung Damage?
Can therapeutics used in the treatment of cancer be a breakthrough for pulmonary disease? Specifically, chronic obstructive pulmonary disease (COPD)? &ldqu
JAN 11, 2020
Genetics & Genomics
JAN 11, 2020
Single Cells Carry 'Forests' of Chromatin
Researchers are learning more about how every human cell organizes and packages about two meters of DNA.
JAN 15, 2020
Cell & Molecular Biology
JAN 15, 2020
Cell Division Research Reveals More About a Protein That's Elevated in Cancer
Cell division is a carefully regulated process, cancer is the result when it gets out of control.
FEB 14, 2020
FEB 14, 2020
Rewired natural killer cells show promising results in leukemia patients
Natural killer (NK) cells are a subset of white blood cells that are key players in the innate immune system, orchestrat...
MAR 02, 2020
Genetics & Genomics
MAR 02, 2020
DNA Replication Discovery May Lead to New Cancer Treatments
Researchers have learned more about DNA replication during cell division, and their insights may help create new types of cancer therapeutics
MAR 05, 2020
Health & Medicine
MAR 05, 2020
Colorectal Cancers on the Rise in Younger People
Colorectal cancer rates are rising among young Americans, according to the most recent report from the American Cancer Society (ACS). Every three years, th
Loading Comments...